Add Yahoo as a preferred source to see more of our stories on Google. What makes promising pancreatic cancer drug different from chemotherapy? 01:54 A new, experimental medication nearly doubled ...

"The number of men living with prostate cancer also continues to rise, so it's vital that we see investment in prostate ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...

A pooled analysis of four clinical trials finds that liver metastases are a strong negative prognostic factor for ...

At 30 months, mitazalimab plus mFOLFIRINOX achieved an OS rate of 21% in patients with previously untreated metastatic PDAC. Mitazalimab plus leucovorin, fluorouracil, irinotecan, and oxaliplatin at ...

A prospective controlled study in BMC Medicine found that adding hepatic arterial infusion chemotherapy to lenvatinib and a ...

When Alternative Therapies Meet Breast Cancer Researchers recently examined the treatment choices made by women with breast ...

First-line nivolumab plus chemotherapy provides a durable survival benefit in advanced gastric cancers, particularly in patients with a PD-L1 CPS of 5 or higher. Nivolumab (Opdivo) in combination with ...

Mumbai: Doctors at Tata Memorial Hospital (TMH) have found that adding an affordable, decades-old platinum-based drug to current chemotherapy options "significantly" improved survival rates for young ...

Tagrisso plus chemotherapy improved progression-free survival in EGFR-positive NSCLC patients compared to placebo plus chemotherapy, with median survival of 8.4 vs. 4.4 months. Central nervous system ...

A drug that targets a molecular pathway involved in many types of cancer extends survival rate of pancreatic cancer patients by more than a year on average, according to new results from a clinical ...